<?xml version="1.0" encoding="UTF-8"?>
<p>Small clinical experiences have been published with the use of donor pool intravenous immunoglobulin (IVIG) [
 <xref rid="B7-vaccines-08-00224" ref-type="bibr">7</xref>,
 <xref rid="B177-vaccines-08-00224" ref-type="bibr">177</xref>]. Their role is unclear, nevertheless IVIG may have both a partial inhibitory viral effect due to nonspecific cross-reaction, and a well-known immunomodulatory effect in several inflammatory conditions, including macrophage activation syndrome [
 <xref rid="B178-vaccines-08-00224" ref-type="bibr">178</xref>]. IVIG use may be most relevant in patients with specific organ involvement such as myocarditis and Guillan-Barr√© syndrome, which have also been reported in association with SARS CoV-2 infection [
 <xref rid="B179-vaccines-08-00224" ref-type="bibr">179</xref>].
</p>
